Kuros Biosciences Expands into Extremities Markets

Kuros Biosciences AG has announced its strategic expansion into the extremities markets. The appointment of Jantzen Cole as Vice President of Market Development is set to drive the company's growth beyond the spine market. This expansion opens a new market opportunity estimated at $1 billion.

With over two decades of experience in orthopedics, Mr. Cole will lead the development of Kuros' market strategy. His leadership is expected to leverage existing hospital approvals and infrastructure, building on the company's proven track record in the spine market. MagnetOs formulations are already approved for use beyond spine procedures, enhancing their potential in extremities.

A dedicated Surgeon Advisory Board has also been formed. The board will guide the introduction of MagnetOs in extremities markets. Kuros aims to solidify its position as a leader in advanced bone healing technologies by the end of 2024.